EXTra-SCI: Exoskeleton and Spinal Cord Injury

Sponsor
McGuire Research Institute (Other)
Overall Status
Completed
CT.gov ID
NCT03410550
Collaborator
(none)
20
1
1
42
0.5

Study Details

Study Description

Brief Summary

The purpose of the current study is to investigate the effects of powered exoskeleton (EKSO) on cardiovascular performance as measured by resting blood pressure and heart rate, peak oxygen consumption during walking, energy expenditure, whole and regional body composition assessments. The effects of exoskeleton training on walking kinematics including stand-up time, walking time, distance covered and speed of walking will also be evaluated.

Condition or Disease Intervention/Treatment Phase
  • Device: Exoskeleton Training
Phase 2

Detailed Description

Powered exoskeletons using robotic suits have recently been introduced for the rehabilitation of persons with spinal cord injury (SCI). Exoskeletons offer a unique opportunity for persons with SCI to experience standing and walking at a low metabolic cost. Evidence suggested that exoskeleton assisted walking can decrease spasticity and improve bowel movement. Training may also improve the level of physical activity as well as psychological parameters that are likely to interfere with rehabilitation outcomes. Previous studies reported that a frequency of 2-3 times per week or more for 1-2 hours may be beneficial in the rehabilitation of persons with SCI. Using exoskeletal-assisted walking to improve the level of physical activity may be appealing to persons with SCI.

Exoskeleton training for 12 weeks may enhance energy expenditure, parameters of physical activity and result only on modest effects on both cardiovascular and body composition parameters. In other words, persons with tetraplegia may have greater cardiovascular and body composition adaptations compared to persons with paraplegia. Twenty subjects will participate in a powered exoskeleton (EKSO) for one or twice a week for 12 weeks. The program will involve walking with the robotic suits for 1 hour for persons with complete (n=10) and persons with incomplete (n=10) SCI.

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Twenty subjects will participate in a powered exoskeleton (EKSO) for one or twice a week for 12 weeks. The program will involve walking with the robotic suits for 1 hour for persons with complete (n=10) and persons with incomplete (n=10) SCI.Twenty subjects will participate in a powered exoskeleton (EKSO) for one or twice a week for 12 weeks. The program will involve walking with the robotic suits for 1 hour for persons with complete (n=10) and persons with incomplete (n=10) SCI.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Exoskeleton Training After Spinal Cord Injury
Actual Study Start Date :
Jul 1, 2018
Actual Primary Completion Date :
Dec 30, 2021
Actual Study Completion Date :
Dec 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Exoskeleton Training

Twenty men with complete and incomplete SCI will be enrolled in the trial.

Device: Exoskeleton Training
Twenty subjects will participate in a powered exoskeleton (EKSO) for one or twice a week for 12 weeks. The program will involve walking with the robotic suits for 1 hour for persons with complete (n=10) and persons with incomplete (n=10).

Outcome Measures

Primary Outcome Measures

  1. Blood Pressure (mmHg) [12 weeks]

    Resting blood pressure and post-exercise blood pressure will be measured every visit.

  2. Walking time (minutes) [12 weeks]

    The robotic unit will measure standing up time, walking time and walking distance for every visit.

  3. Oxygen uptake (l/min) [12 weeks]

    Oxygen uptake will be measured during sitting, standing and walking at the beginning and at the end of the training program.

  4. Body Composition (kg) [12 weeks]

    Body composition using dual energy x-ray absorptiometry anthropometrics' will be measured during sitting, standing and walking at the beginning and at the end of the training program.

Secondary Outcome Measures

  1. Six minute-walk Test (meter) [12 weeks]

    The test will competed at the beginning and at the end of study to measure distance.

  2. Walking Index for Spinal Cord Injury II (WISCI II) [12 weeks]

    The test will competed at the beginning and at the end of study

  3. Electromyography (EMG) activity of 6 muscle groups (mV) [12 weeks]

    The test will competed at the beginning and at the end of study

  4. Mitochondrial health using near infra-red spectroscopy (seconds) [12 weeks]

    The test will competed at the beginning and at the end of study

  5. 10 meter walk Test (m/sec) [12 weeks]

    The test will competed at the beginning and at the end of study to measure speed.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. A written clearance by the medical doctor .

  2. Participants will have to be 1 year post-injury with any level of injury.

  3. All participants will be between 18-70 years old, men/women,

Exclusion Criteria:
  1. Participants with body weight greater than 220 lbs

  2. Whole body T-scores less than -2.5 standard deviation will result in elimination from the program.

  3. Hip width, upper leg length and lower leg length that do not fit in the robotic suit.

  4. Previous unhealed fracture in both lower or upper extremities

  5. Leg length discrepancy that is unlikely to be managed by having shoe inserts

  6. High resting blood pressure greater than 130/80 mmHg

  7. Sudden drop in blood pressure by 20 mmHg especially in persons with tetraplegia.

  8. Medical conditions prior enrollment similar to cardiovascular disease, uncontrolled type II diabetes mellitus, uncontrolled hypertension, and those on insulin, pressures sores stage 2 or greater, or urinary tract infection or symptoms.

  9. Pregnancy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hunter Holmes McGuire VA Medical Center Richmond Virginia United States 23249

Sponsors and Collaborators

  • McGuire Research Institute

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Ashraf Gorgey, Director of SCI Research, McGuire Research Institute
ClinicalTrials.gov Identifier:
NCT03410550
Other Study ID Numbers:
  • 02375
First Posted:
Jan 25, 2018
Last Update Posted:
Feb 16, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 16, 2022